Ashland to host live 2023 Innovation Day

WILMINGTON, Del., July 27, 2023 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) will host a live Innovation Day on Tuesday, September 12, 2023 beginning at 9:00 a.m. ET at the company’s corporate headquarters in Wilmington, Delaware.

Interested participants must register for the event and have the option to attend via live webcast or in person. Early registration is encouraged because in person seating is limited. To register, participants should use the following link:


https://onlinexperiences.com/Launch/QReg/ShowUUID=EBE1B154-2E95-4D17-A839-01D9068D8F5A

Utilizing a coordinated and market-based approach, Ashland is developing novel specialty ingredients and additives to create long-term value for its customers and expanding core and adjacent markets. This event will showcase how technology is a playing a critical role in Ashland’s long-term profitable growth strategy and highlight the company’s innovation playbook and portfolio of scalable technologies.

The event will include presentations, prepared remarks, and a moderated question-and-answer (Q&A) session with members of Ashland’s executive leadership team. The event will also include poster sessions and guided tours of Ashland’s research and development laboratories for in-person attendees.

Participants include:

  • Guillermo Novo, chair, and chief executive officer
  • Osama Musa, senior vice president and chief technology officer
  • Jim Minicucci, senior vice president, strategy, mergers and acquisitions and portfolio management
  • Kevin Willis, senior vice president and chief financial officer
  • Ashok Kalyana, senior vice president and general manager, Life Sciences and Intermediates
  • Min Chong, senior vice president and general manager, Personal Care and Specialty Additives
  • Seth Mrozek, director investor relations

Registration information and further event details will be posted on Ashland’s investor website at http://investor.ashland.com

An audio webcast of the event will be available live and can be accessed, along with supporting materials, though the Ashland website. A replay will be available within 24 hours of the live event and will be archived, along with supporting materials, on Ashland’s website for 12 months. Copies of the presentation may also be requested by sending an email to [email protected]

About Ashland 
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Media Relations:
Seth A. Mrozek Carolmarie C. Brown
+1 (302) 594-5010 +1 (302) 995-3158

[email protected]

[email protected]

Attachment



LiveWire Group, Inc. Reports Second Quarter Financial Results

LiveWire Group, Inc. Reports Second Quarter Financial Results

MILWAUKEE–(BUSINESS WIRE)–
LiveWire Group, Inc. (“LiveWire”) (NYSE: LVWR) today reported second quarter results.

“Throughout Q2, we saw high anticipation for Del Mar™, the first bike on the S2 platform, from both riders and our retail partners. With the first bikes rolling off the line in the third quarter, we’re looking forward to getting Del Mar to more and more riders throughout the back half of 2023. During the quarter, we also saw keen interest in the LiveWire brand in the European market in response to our launch events in Berlin, Paris, London and Amsterdam,” said Karim Donnez, CEO, LiveWire.

Second Quarter 2023 Business Highlights

  • Continued activities in final supply chain, regulatory and manufacturing for expected start of production of Del Mar in third quarter

  • Continued product development efforts on third motorcycle in LiveWire family (second on new S2 platform)

  • Activated a network of 35 retail partners in France, the UK, Germany and the Netherlands in support of our hybrid go-to-market model

  • LiveWire ONE® became available in the European market in late June, while preparing to ship the Del Mar Launch Edition later this year

LiveWire Group, Inc. – Unit Results

 

$ in millions, except units

2nd quarter

2023

2022

Change

LiveWire ONE (units)

33

204

(84%)

Harley-Davidson LiveWire (units)

21

(100%)

Electric Motorcycle Shipments (units)

33

225

(85%)

Second Quarter 2023 Results

LiveWire Group, Inc. – Consolidated Results

 

$ in millions, except units *

2nd quarter

2023

2022

Change

Consolidated Revenue

$7.0

$12.5

(44%)

Electric Motorcycles

$0.8

$5.1

(85%)

STACYC

$6.3

$7.4

(15%)

 

 

 

 

Consolidated Operating Income (Loss)

($32.0)

($19.4)

65%

Electric Motorcycles

($31.9)

($20.2)

58%

STACYC

($0.1)

$0.8

(110%)

 

 

 

 

Net Loss

($40.7)

($19.6)

108%

*Amounts may not add up due to rounding

 

LiveWire Group, Inc. consolidated net loss was $40.7 million for the second quarter as compared to $19.6 million in the same period prior year driven by the below segment results, planned product development investment, as well as a $11.4 million non-operating mark-to-market expense related to the increase in fair value of the outstanding warrants as of the end of the quarter.

LiveWire Group, Inc. is comprised of two business segments:

  • Electric Motorcycles – focused on the sale of electric motorcycles and related products

  • STACYC – focused on the sale of electric balance bikes for kids and related products

Electric Motorcycles

Electric Motorcycle revenue was down compared to the same quarter in the prior year due to lower unit sales of LiveWire ONE. In line with expectations, increased operating losses versus the second quarter of 2022 were the result of the planned product development investments to advance the electric vehicle systems and activities associated with launch preparation of the Del Mar and the development of LiveWire’s third motorcycle. Increased operating losses also incorporate the added planned costs of standing up a new organization as compared to the same quarter in the prior year.

STACYC

STACYC revenue was down in the second quarter due to our retail partners for electric balance bikes taking a more conservative approach to inventory in response to the macro-economic environment as compared to the second quarter of 2022. STACYC operating loss for the second quarter was $0.1 million versus operating income of $0.8 million a year ago, largely due to gross margin driven by lower volumes.

2023 Financial Outlook

For the full year 2023, the Company is revising its unit sales guidance and now expects:

  • Electric Motorcycle unit sales of 600 to 1,000

For the full year 2023, the Company reaffirms its initial guidance and continues to expect:

  • LiveWire Group Operating Loss of $115 to $125 million

Liquidity

To support future ongoing operations, the Company has the following available liquidity:

  • Cash and cash equivalents as of the end of Q2 2023 of $216 million

  • A non-binding $200 million term sheet with majority shareholder

Webcast

The public is invited to attend an audio webcast from 8-9 a.m. CT. LiveWire leadership will be joining the Harley-Davidson, Inc. audio webcast to discuss our results, developments in the business, and updates to the Company’s outlook. The webcast login can be accessed at https://investor.livewire.com/news-events-1/events/default.aspx. The audio replay will be available by approximately 10:00 a.m. CT.

About LiveWire

LiveWire has a dedicated focus on the electric motorcycle sector. LiveWire’s majority shareholder is Harley-Davidson, Inc. LiveWire comes from the lineage of Harley-Davidson and is capitalizing on a decade of its learnings in the EV sector. With a dedicated focus on EV, LiveWire plans to develop the technology of the future and to invest in the capabilities needed to lead the transformation of motorcycling. www.livewire.com

Cautionary Note Regarding Forward-Looking Statements

The Company intends that certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Words or phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described in prior public filings titled “Risk Factors.” These forward-looking statements are subject to numerous risks, including, without limitation, the following: our history of losses and expectation to incur significant expenses and continuing losses for the foreseeable future; our limited operating history, the rollout of our business and the timing of expected business milestones, including our ability to develop and manufacture electric vehicles of sufficient quality and appeal to customers on schedule and on a large scale; our financial and business performance, including financial projections and business metrics and any underlying assumptions thereunder; changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; our ability to attract and retain a large number of customers; our future capital requirements and sources and uses of cash; our ability to obtain funding for our operations and manage costs; challenges we face as a pioneer into the highly-competitive and rapidly evolving electric vehicle industry; our operational and financial risks if we fail to effectively and appropriately separate the LiveWire business from the H-D business; H-D making decisions for its overall benefit that could negatively impact our overall business; our relationship with H-D and its impact on our other business relationships; our ability to leverage contract manufacturers, including H-D and Kwang Yang Motor Co., Ltd., a Taiwanese company (“KYMCO”), to contract manufacture our electric vehicles; retail partners being unwilling to participate in our go-to-market business model or their inability to establish or maintain relationships with customers for our electric vehicles; potential delays in the design, manufacture, financing, regulatory approval, launch and delivery of our electric vehicles; building out our supply chain, including our dependency on our existing suppliers and our ability to source suppliers, in each case many of which are single-sourced or limited-source suppliers, for our critical components such as batteries and semiconductor chips; our ability to rely on third-party and public charging networks; our ability to attract and retain key personnel; our business, expansion plans and opportunities, including our ability to scale our operations and manage our future growth effectively; the effects on our future business of competition, the pace and depth of electric vehicle adoption generally and our ability to achieve planned competitive advantages with respect to our electric vehicles and products, including with respect to reliability, safety and efficiency; our business and H-D’s business overlapping and being perceived as competitors; our inability to maintain a strong relationship with H-D or to resolve favorably any disputes that may arise between us and H-D; our dependency on H-D for a number of services, including services relating to quality and safety testing. If those service arrangements terminate, it may require significant investment for us to build our own safety and testing facilities, or we may be required to obtain such services from another third-party at increased costs; any decision by us to electrify H-D products, or the products of any other company; our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; potential harm caused by misappropriation of our data and compromises in cybersecurity; changes in laws, regulatory requirements, governmental incentives and fuel and energy prices; the impact of health epidemics, including the COVID-19 pandemic, on our business, the other risks we face and the actions we may take in response thereto; litigation, regulatory proceedings, complaints, product liability claims and/or adverse publicity; and the possibility that we may be adversely affected by other economic, business and/or competitive factors. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. Some of these risks and uncertainties may in the future be amplified by new risk factors and uncertainties that may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should read this earnings release completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

 

 

LiveWire Group, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

Three months ended

 

Six months ended

 

June 30,

2023

 

June 26,

2022

 

June 30,

2023

 

June 26,

2022

Revenue, net

$

7,026

 

 

$

12,506

 

 

$

14,788

 

 

$

22,907

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of goods sold

 

9,966

 

 

 

12,896

 

 

 

16,464

 

 

 

23,244

 

Selling, administrative and engineering expense

 

29,044

 

 

 

18,966

 

 

 

55,215

 

 

 

34,718

 

Total costs and expenses

 

39,010

 

 

 

31,862

 

 

 

71,679

 

 

 

57,962

 

Operating loss

 

(31,984

)

 

 

(19,356

)

 

 

(56,891

)

 

 

(35,055

)

Other income, net

 

 

 

 

87

 

 

 

 

 

 

156

 

Interest expense related party

 

 

 

 

(198

)

 

 

 

 

 

(475

)

Interest income (expense)

 

2,754

 

 

 

(16

)

 

 

5,446

 

 

 

(20

)

Change in fair value of warrant liabilities

 

(11,438

)

 

 

 

 

 

(10,370

)

 

 

 

Loss before income taxes

 

(40,668

)

 

 

(19,483

)

 

 

(61,815

)

 

 

(35,394

)

Income tax provision

 

64

 

 

 

95

 

 

 

64

 

 

 

163

 

Net loss

$

(40,732

)

 

$

(19,578

)

 

$

(61,879

)

 

$

(35,557

)

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

$

(0.20

)

 

$

(0.12

)

 

$

(0.31

)

 

$

(0.22

)

 

 

 

 

 

 

 

 

Weighted-average shares, basic and diluted

 

202,409

 

 

 

161,000

 

 

 

202,407

 

 

 

161,000

 

 

 

LiveWire Group, Inc.

Consolidated Balance Sheets

(In thousands)

 

 

(Unaudited)

 

 

 

June 30,

2023

 

December 31,

2022

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

215,872

 

 

$

265,240

 

Accounts receivable, net

 

4,677

 

 

 

2,325

 

Accounts receivable from related party

 

407

 

 

 

525

 

Inventories, net

 

32,174

 

 

 

29,215

 

Other current assets

 

2,720

 

 

 

4,625

 

Total current assets

 

255,850

 

 

 

301,930

 

Property, plant and equipment, net

 

35,678

 

 

 

31,567

 

Goodwill

 

8,327

 

 

 

8,327

 

Lease assets

 

2,538

 

 

 

3,128

 

Intangible assets, net

 

1,578

 

 

 

1,809

 

Other long-term assets

 

6,490

 

 

 

5,044

 

Total assets

$

310,461

 

 

$

351,805

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

6,072

 

 

$

7,055

 

Accounts payable to related party

 

16,324

 

 

 

5,733

 

Accrued liabilities

 

17,047

 

 

 

20,343

 

Current portion of lease liabilities

 

1,385

 

 

 

1,312

 

Total current liabilities

 

40,828

 

 

 

34,443

 

Long-term portion of lease liabilities

 

1,244

 

 

 

1,913

 

Deferred tax liabilities

 

78

 

 

 

15

 

Warrant liabilities

 

18,757

 

 

 

8,388

 

Other long-term liabilities

 

425

 

 

 

246

 

Total liabilities

 

61,332

 

 

 

45,005

 

Shareholders’ equity:

 

 

 

Preferred Stock

 

 

 

 

 

Common Stock

 

20

 

 

 

20

 

Additional paid-in-capital

 

333,426

 

 

 

329,218

 

Accumulated deficit

 

(84,317

)

 

 

(22,438

)

Total shareholders’ equity

 

249,129

 

 

 

306,800

 

Total liabilities and shareholders’ equity

$

310,461

 

 

$

351,805

 

 

 

LiveWire Group, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

Six months ended

 

June 30,

2023

 

June 26,

2022

Cash flows from operating activities:

 

 

 

Net loss

$

(61,879

)

 

$

(35,557

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

Depreciation and amortization

 

1,372

 

 

 

2,806

 

Payment of contingent consideration in excess of acquisition date fair value

 

 

 

 

(413

)

Change in fair value of warrant liabilities

 

10,370

 

 

 

 

Stock compensation expense

 

4,202

 

 

 

(171

)

Provision for doubtful accounts

 

55

 

 

 

27

 

Deferred income taxes

 

63

 

 

 

82

 

Inventory write-downs

 

1,626

 

 

 

597

 

Cloud computing arrangements development costs

 

(640

)

 

 

(1,158

)

Other, net

 

(629

)

 

 

(511

)

Changes in current assets and liabilities:

 

 

 

Accounts receivable, net

 

(2,407

)

 

 

3,064

 

Accounts receivable from related party

 

118

 

 

 

(1,124

)

Inventories

 

(4,585

)

 

 

(11,321

)

Other current assets

 

1,905

 

 

 

1,892

 

Accounts payable and accrued liabilities

 

(1,357

)

 

 

4,143

 

Accounts payable to related party

 

10,591

 

 

 

 

Net cash used by operating activities

 

(41,195

)

 

 

(37,644

)

Cash flows from investing activities:

 

 

 

Capital expenditures

 

(8,175

)

 

 

(5,722

)

Net cash used by investing activities

 

(8,175

)

 

 

(5,722

)

Cash flows from financing activities:

 

 

 

Proceeds received from exercise of warrants

 

2

 

 

 

 

Borrowings on notes payable to related party

 

 

 

 

15,333

 

Payment of contingent consideration up to acquisition date fair value

 

 

 

 

(1,767

)

Transfers from H-D

 

 

 

 

32,497

 

Net cash provided by financing activities

 

2

 

 

 

46,063

 

Net (decrease) increase in cash and cash equivalents

$

(49,368

)

 

$

2,697

 

 

 

 

 

Cash and cash equivalents:

 

 

 

Cash and cash equivalents—beginning of period

$

265,240

 

 

$

2,668

 

Net (decrease) increase in cash and cash equivalents

 

(49,368

)

 

 

2,697

 

Cash and cash equivalents—end of period

$

215,872

 

 

$

5,365

 

 

Media Contact: Jenni Coats (414) 343-7902

Financial Contact: Shawn Collins (414) 343-8002

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Motorcycles General Automotive Automotive EV/Electric Vehicles

MEDIA:

Logo
Logo

EVgo Introduces “Charge Talk” Video Series to Answer Current and Future EV Drivers’ Biggest Questions on EV Charging

EVgo Introduces “Charge Talk” Video Series to Answer Current and Future EV Drivers’ Biggest Questions on EV Charging

New video series featuring EVgo leadership debuts as part of ongoing commitment to customer education

LOS ANGELES–(BUSINESS WIRE)–
EVgo Inc. (NASDAQ: EVGO) (“EVgo” or the “Company”), one of the nation’s largest public fast charging networks for electric vehicles (EVs), announced the launch of “Charge Talk,” a new video series dedicated to educating current and prospective EV drivers on the latest hot topics and frequently asked questions related to EV charging. The first three episodes are available online, with new episodes from the first installment of the series to be released each month. The most recent installment features a discussion on CCS and the North American Charging Standard (NACS) connectors and what EV drivers may expect to see in the future as charging networks like EVgo evolve to meet consumer needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727625617/en/

EVgo's Chief Operating Officer (left), Dennis Kish, and Chief Technology Officer (right), Ivo Steklac, on the set of the company's new video series “Charge Talk". (Photo: Business Wire)

EVgo’s Chief Operating Officer (left), Dennis Kish, and Chief Technology Officer (right), Ivo Steklac, on the set of the company’s new video series “Charge Talk”. (Photo: Business Wire)

“Charge Talk” builds on EVgo’s steadfast commitment to education and transparency in support of mass EV adoption and charging infrastructure expansion. In 2021, the Company launched Connect the Watts™, an initiative focused on bringing the EV charging infrastructure community together to identify best practices and accelerate fast charger deployment. Earlier this year, EVgo announced EVgo ReNew™, its enhanced and comprehensive network upgrade program designed to advance uptime and boost range confidence for all EV drivers. As a complement to EVgo ReNew, the “Charge Talk” series will focus on consumer education, hoping to increase successful charging sessions for EV drivers.

With EV sales skyrocketing, industry analysts have estimated that more than 300,000 public fast chargers will be needed by 2030 to meet EV charging demand. As public charging expands and reaches new areas, first-time EV drivers are learning about the distinct aspects of EV ownership and are searching for information to get the best charging experience. EVgo continues to expand its network footprint in collaboration with automakers and site host partners to serve these drivers, and the Company is adding to its roster of educational content to support a seamless transition to the EV lifestyle through “Charge Talk” and other short videos presented by experts on the team. Topics include session initiation, charging speeds, how to pay for charging and more.

“EVgo is committed to delivering a great customer experience. With all the new EV drivers hitting the road, we want to make sure they have the resources they need to use public fast charging successfully,” said Dennis Kish, Chief Operating Officer at EVgo. “One of the simplest (but not necessarily the most intuitive) pieces of advice we give first-time EV drivers is to always follow the directions on the charger screen and plug in the connector first. The momentum we’re seeing in electrification is inspiring, and we remain dedicated to our educational efforts to help drivers make the transition to clean transportation with confidence.”

Based on questions and comments that EVgo receives via social media and email, as well as trending topics in news articles and reports, episodes of the new series will address often-asked questions and debunk common misconceptions for new EV owners and those considering purchasing an EV.

To watch episodes of EVgo’s “Charge Talk” series, EVgo ReNew videos and other EVgo short topics, visit the EVgo YouTube page.

About EVgo

EVgo (Nasdaq: EVGO) is a leader in charging solutions, building and operating the infrastructure and tools needed to expedite the mass adoption of electric vehicles for individual drivers, rideshare and commercial fleets, and businesses. Since 2019, EVgo has purchased renewable energy certificates to match the electricity that powers its network. As one of the nation’s largest public fast charging networks, EVgo’s owned and operated charging network includes around 900 fast charging locations, 60 metropolitan areas and 30 states. EVgo continues to add more DC fast charging locations across the U.S., including stations built through EVgo eXtend™, its white label service offering. EVgo is accelerating transportation electrification through partnerships with automakers, fleet and rideshare operators, retail hosts such as grocery stores, shopping centers, and gas stations, policy leaders, and other organizations. With a rapidly growing network, robust software products and unique service offerings for drivers and partners including EVgo Optima™, EVgo Inside™, EVgo Rewards™, and Autocharge+, EVgo enables a world-class charging experience where drivers live, work, travel and play.

For Investors:

[email protected]

For Media:

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Automotive Manufacturing Alternative Energy Energy Green Technology Manufacturing Online Alternative Vehicles/Fuels Technology Apps/Applications EV/Electric Vehicles Batteries Environment Automotive Software Entertainment

MEDIA:

Logo
Logo
Photo
Photo
EVgo’s Chief Operating Officer (left), Dennis Kish, and Chief Technology Officer (right), Ivo Steklac, on the set of the company’s new video series “Charge Talk”. (Photo: Business Wire)

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on August 3, 2023, and will host a conference call at 8:30 a.m. ET that day.

To access the August 3 conference call via phone, please dial +1 (800) 715-9871 (US) or +1 (646) 307-1963 (International) and ask to join the Kymera Therapeutics call or provide Conference ID 7353312. A live webcast of the Company’s conference call will be available under the “Events and Presentations” section of the Investors page on the Company’s website at www.kymeratx.com.

About Kymera Therapeutics

Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces. For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements by Kymera Therapeutics regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD, STAT3, and MDM2 degrader programs; plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof; expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current and future preclinical studies and clinical trials, supply chain, strategy and future operations; the delay of any current and future preclinical studies or clinical trials or the development of Kymera Therapeutics’ drug candidates; the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for KT-474, KT-333, KT-413 and KT-253; Kymera Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Kymera Therapeutics’ planned interactions with regulatory authorities; obtaining, maintaining and protecting its intellectual property; and Kymera Therapeutics’ relationships with its existing and future collaboration partners. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 filed on May 4, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics’ subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact:   Media Contact:
     
Bruce Jacobs   Todd Cooper
Chief Financial Officer   Senior Vice President, Corporate Affairs
[email protected]   [email protected]
857-285-5300   857-285-5300
     
Chris Brinzey    
Managing Director, Westwicke    
[email protected]    
339-970-2843    



D-Wave Announces Collaborations to Advance Quantum Coherence

D-Wave Announces Collaborations to Advance Quantum Coherence

Funded by NSERC grants, the work with researchers from the Institute for Quantum Computing at the University of Waterloo focuses on key hardware advancements for quantum computing systems

BURNABY, British Columbia & PALO ALTO, Calif. & WATERLOO, Ontario–(BUSINESS WIRE)–D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, today announced two new collaborations with the Institute for Quantum Computing (IQC) at the University of Waterloo. These collaborations establish key hardware research programs for quantum computing systems.

The two multi-year projects between D-Wave and the researchers were funded through the Natural Sciences and Engineering Research Council of Canada (NSERC) Quantum Alliance program, which is part of Canada’s National Quantum Strategy. These projects will focus on identifying improvements in device design and materials quality that support increasingly coherent superconducting quantum processors.

“Quantum computing has the potential to revolutionize how we tackle societal problems. Key to this transformation is the ability to provide larger quantum systems with greater coherence, and these NSERC projects each facilitate important R&D for these next-generation systems,” said Dr. Alan Baratz, CEO of D-Wave. “We’re excited to engage with the University of Waterloo through the NSERC program to further build out a robust quantum ecosystem that can tackle real-world problems.”

“The collaboration with D-Wave will provide a unique opportunity to explore fundamental aspects of the physics of a new generation of superconducting qubits, which have the potential to enable new quantum computing architectures,” said Dr. Adrian Lupascu, professor at the Institute for Quantum Computing and Department of Physics and Astronomy at the University of Waterloo.

“I would like to thank NSERC for the opportunity to collaborate with D-Wave. These funds provide essential support for my research team to work with D-Wave on developing improved superconducting components for quantum computing and quantum devices. In addition, the collaboration will contribute to building up Canada’s quantum-ready workforce, as my team gains valuable experience in the fast-growing cryogenic and quantum computing sector,” said Dr. Jan Kycia, Physics and Astronomy professor at the University of Waterloo and Institute for Quantum Computing affiliate.

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. Our mission is to unlock the power of quantum computing today to benefit business and society. We do this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this press release include, but are not limited to, statements regarding the focus and results of the collaborations between D-Wave and the University of Waterloo, the potential of quantum computing, what is needed to realize the potential of quantum computing, and the opportunities arising from the collaborations between D-Wave and the University of Waterloo. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks, our ability to expand our customer base and the customer adoption of our solutions, and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of the our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; and the risk that our securities will not maintain the listing on the NYSE. Furthermore, if the forward-looking statements contained in this press release prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

D-Wave

Amy McDowell

[email protected]

University of Waterloo

Samantha Clark

[email protected]

KEYWORDS: California United States North America Canada

INDUSTRY KEYWORDS: Education Technology Software Research Science University Hardware

MEDIA:

Logo
Logo

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time

Company plans to update full year 2023 XHANCE net revenue guidance on August 10

YARDLEY, Pa., July 27, 2023 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $19.5 million for the three months ended June 30, 2023.

“Our preliminary second quarter net product revenue of $19.5 million contributes to a first half 2023 performance that exceeded our initial expectations,” stated CEO Ramy Mahmoud. “We look forward to providing a complete update of our recent commercial performance and regulatory progress on the tenth of August.”

The financial information included in this release is preliminary and is subject to change. The Company expects to report full financial results for the second quarter of 2023 and corporate updates, including full year 2023 net product revenue guidance, before market open on Thursday, August 10, 2023.

Company to Host Conference Call 

Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 10, 2023. 

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at http://ir.optinose.com/event-calendar. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event. 

About Optinose

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: preliminary XHANCE® net product revenue of $19.5 million for the quarter ended June 30, 2023; the Company’s expectation to report full financial results for the second quarter of 2023 and corporate updates, including full year 2023 net product revenue guidance, before market open on Thursday, August 10, 2023; and other statements regarding the Company’s future operations, financial performance, financial position, prospects, objectives; and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the potential for preliminary XHANCE net product revenue for the quarter ended June 30, 2023 to change in connection with the finalization of the Company’s financial results for the second quarter of 2023; and the risks, uncertainties and other factors discussed under the caption “Item 1A. Risk Factors” and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission – which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.

Optinose Investor Contact

Jonathan Neely
[email protected]
267.521.0531



Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2023

BANNOCKBURN, Ill., July 27, 2023 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2023.


Second Quarter 2023 Financial Results and Highlights

  • Net revenue of $1,069.1 million, up 9.0% compared to $980.8 million in the second quarter of 2022
  • Gross profit of $250.8 million, or 23.5% of net revenue, up 15.6% compared to $216.9 million, or 22.1% of net revenue, in the second quarter of 2022
  • Net income of $114.4 million, or $0.64 basic earnings per share, up 237.2% compared to net income of $33.9 million, or $0.19 basic earnings per share, in the second quarter of 2022
  • Adjusted EBITDA of $110.1 million, up 29.2% compared to $85.2 million in the second quarter of 2022
  • Cash flow from operations of $169.5 million compared to $104.4 million in the second quarter of 2022
  • Cash and cash equivalents balance was $441.2 million at the end of the second quarter of 2023
  • Entered into and subsequently terminated the Merger Agreement with Amedisys, Inc. and received a payment of $106.0 million in cash on behalf of Amedisys

John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team executed on another solid quarter of financial results. Our commitment to providing unparalleled care that produces superior clinical outcomes makes us confident in our continued growth trajectory as we head into the back half of the year.”


Updated Full Year 2023 Financial Guidance

For the full year 2023, Option Care Health expects to generate:

  • Net Revenue of $4.2 billion to $4.3 billion
  • Adjusted EBITDA of $415 million to $425 million
  • Cash Flow from Operations of at least $350 million, inclusive of Amedisys termination fee, net of expenses

Additionally, the Company continues to anticipate an effective tax rate of 27% to 29% and net interest expense of approximately $55.0 million to $59.0 million.


Conference Call

Option Care Health will host a conference call to discuss its second quarter 2023 financial results later today at 8:30 a.m. EDT. The conference call can be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.


About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.


Investor Contacts

Mike Shapiro Bob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial Officer Westwicke
T: (312) 940-2538 T: (413) 213-0500

[email protected]

[email protected]
   


Forward-Looking Statements – Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or
a measure of the Company’s liquidity. In addition, the Company’s definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

Schedule 1

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)(UNAUDITED)

 

  June 30, 2023   December 31, 2022
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents $ 441,166   $ 294,186
Accounts receivable, net   396,501     377,542
Inventories   262,924     224,281
Prepaid expenses and other current assets   97,629     98,330
Total current assets   1,198,220     994,339
       
NONCURRENT ASSETS:      
Property and equipment, net   106,777     108,321
Intangible assets, net   21,645     22,371
Referral sources, net   330,948     341,744
Goodwill   1,540,567     1,533,424
Other noncurrent assets   122,741     112,737
Total noncurrent assets   2,122,678     2,118,597
TOTAL ASSETS $ 3,320,898   $ 3,112,936
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable $ 467,666   $ 378,763
Other current liabilities   200,801     186,588
Total current liabilities   668,467     565,351
       
NONCURRENT LIABILITIES:      
Long-term debt, net of discount, deferred financing costs and current portion   1,057,391     1,058,204
Other noncurrent liabilities   119,657     103,278
Total noncurrent liabilities   1,177,048     1,161,482
Total liabilities   1,845,515     1,726,833
       
STOCKHOLDERS’ EQUITY   1,475,383     1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,320,898   $ 3,112,936

Schedule 2

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

 

  Three Months Ended June 30,   Six Months Ended June 30,
    2023       2022       2023       2022  
NET REVENUE $ 1,069,072     $ 980,820     $ 2,084,920     $ 1,896,604  
COST OF REVENUE   818,243       763,920       1,605,086       1,478,768  
GROSS PROFIT   250,829       216,900       479,834       417,836  
               
OPERATING COSTS AND EXPENSES:              
Selling, general and administrative expenses   153,564       141,787       301,430       275,756  
Depreciation and amortization expense   14,898       16,037       29,412       30,759  
Total operating expenses   168,462       157,824       330,842       306,515  
OPERATING INCOME   82,367       59,076       148,992       111,321  
               
OTHER INCOME (EXPENSE):              
Interest expense, net   (13,196 )     (12,765 )     (27,030 )     (25,011 )
Other, net   86,332       1,327       87,770       2,596  
Total other income (expense)   73,136       (11,438 )     60,740       (22,415 )
               
INCOME BEFORE INCOME TAXES   155,503       47,638       209,732       88,906  
INCOME TAX EXPENSE   41,100       13,709       56,121       24,702  
NET INCOME $ 114,403     $ 33,929     $ 153,611     $ 64,204  
               
Earnings per share, basic $ 0.64     $ 0.19     $ 0.85     $ 0.36  
Earnings per share, diluted $ 0.63     $ 0.19     $ 0.84     $ 0.35  
               
Weighted average common shares outstanding, basic   179,807       180,621       180,531       180,293  
Weighted average common shares outstanding, diluted   181,241       181,618       181,931       181,176  

Schedule 3

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)(UNAUDITED)

 

  Six Months Ended June 30,
    2023       2022  
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income $ 153,611     $ 64,204  
Adjustments to reconcile net income to net cash provided by operations:      
Depreciation and amortization expense   30,801       33,249  
Other non-cash adjustments   38,498       44,371  
Changes in operating assets and liabilities:      
Accounts receivable, net   (18,619 )     (22,950 )
Inventories   (38,643 )     (48,671 )
Accounts payable   88,896       100,924  
Other   4,744       (34,173 )
Net cash provided by operating activities   259,288       136,954  
       
CASH FLOWS FROM INVESTING ACTIVITIES:      
Acquisition of property and equipment   (13,554 )     (10,055 )
Business acquisitions, net of cash acquired   (12,855 )     (59,897 )
Net cash used in investing activities   (26,409 )     (69,952 )
       
CASH FLOWS FROM FINANCING ACTIVITIES:      
Purchase of company stock   (75,000 )      
Proceeds from warrant exercises         20,098  
Other financing cash flows   (10,899 )     (2,477 )
Net cash (used in) provided by financing activities   (85,899 )     17,621  
NET INCREASE IN CASH AND CASH EQUIVALENTS   146,980       84,623  
Cash and cash equivalents – beginning of the period   294,186       119,423  
CASH AND CASH EQUIVALENTS – END OF PERIOD $ 441,166     $ 204,046  

Schedule 4

OPTION CARE HEALTH, INC.

QUARTERLY RECONCILIATION
BETWEEN GAAP AND NON-GAAP MEASURES

(IN THOUSANDS)(UNAUDITED)

 

  Three Months Ended June 30,   Six Months Ended June 30,
  2023   2022   2023   2022
Net income $ 114,403     $ 33,929   $ 153,611     $ 64,204
Interest expense, net   13,196       12,765     27,030       25,011
Income tax expense   41,100       13,709     56,121       24,702
Depreciation and amortization expense   15,576       17,270     30,801       33,249
EBITDA   184,275       77,673     267,563       147,166
               
EBITDA adjustments              
Stock-based incentive compensation   7,685       4,398     13,673       8,576
Restructuring, acquisition, integration and other (1)   (81,910 )     3,105     (77,412 )     7,216
Adjusted EBITDA $ 110,050     $ 85,176   $ 203,824     $ 162,958

(1) Inclusive of Amedisys merger termination fee, net of merger-related expenses

 



NI Announces New LabVIEW Features to Turn Test Performance into Business Performance

NI Announces New LabVIEW Features to Turn Test Performance into Business Performance

New User-Focused Features Include Zoom for Block Diagram

AUSTIN, Texas–(BUSINESS WIRE)–
NI, formerly known as National Instruments, today announced a significant upgrade to its flagship product LabVIEW. For nearly 40 years, LabVIEW has been the industry-standard product in the field of data acquisition, instrument control and automation. These latest improvements further enable engineers in their use of test insights and data to drive product and business performance. The latest improvements include:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727693038/en/

LabVIEW Featuring ZOOM

LabVIEW Featuring ZOOM

  • Zoom for Block Diagram

  • Quick change for faster object creation

  • Double-click to create control or indicator from a wire

  • Visual improvements to Highlight Execution and option for execution speeds

  • Faster re-building of applications and packed project libraries

  • Virtual environment support for Python and LabVIEW users (announced Q1 2023)

“It was exciting to see the appreciation from the audience at NI Connect when we demonstrated the upcoming, ease-of-use improvements with this new version of LabVIEW,” says Eric Reffett, Director of Product Management at NI. “Additions like Zoom and quick change are meaningful in a graphical development environment, and we are energized by both the engagement we got from the community during design, as well as the impact we know it will have.”

In addition, NI and JKI entered a long-term collaboration to focus on improving package-related workflows in LabVIEW. This included expanding VI Package Manager (VIPM) features, making it more robust and versatile for developers, as well as the addition of Dragon. This initial release is focused on using projects and packages, and the relationship will continue to improve the way developers share and re-use code.

“I’m thrilled to work with NI,” says Jim Kring, CEO of JKI. “JKI first created VIPM to help LabVIEW developers build and reuse LabVIEW code libraries, and it has since helped developers for over a decade. This collaboration with NI expands both the functionality available to all LabVIEW developers in VIPM, as well as the access developers have to resources available in VIPM.io, but this initiative is just the beginning.”

The new LabVIEW features have made it more user-friendly, efficient and powerful for helping test professionals and engineers focus on turning test performance into business performance. For more information, visit NI’s LabVIEW page:

https://www.ni.com/en-us/support/downloads/software-products/download.labview.html

About NI

At NI, we bring together the people, ideas and technology so forward thinkers and creative problem solvers can take on humanity’s biggest challenges. From data and automation to research and validation, we provide the tailored, software-connected systems engineers and enterprises need to Engineer Ambitiously™ every day.

National Instruments, NI, ni.com, LabVIEW and Engineer Ambitiously are trademarks of National Instruments Corporation. Other product and company names listed are trademarks or trade names of their respective companies.

NI Corporate Media Relations

Email: [email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Electronic Design Automation Engineering Data Management Technology Manufacturing Software

MEDIA:

Logo
Logo
Photo
Photo
LabVIEW Featuring ZOOM

Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference

CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

A live webcast of the presentation may be accessed by visiting ir.acutusmedical.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company’s website for 90 days.

About Acutus Medical, Inc.

Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Investor Contact

Caroline Corner
ICR Westwicke
D: 415-202-5678
[email protected]

Media Contact

Rhiannon Pickus
442-232-6094
[email protected]



Stericycle, Inc. Reports Results For the Second Quarter 2023

BANNOCKBURN, Ill., July 27, 2023 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today reported results for the second quarter ended June 30, 2023.

Revenues for the second quarter were $669.5 million, a decrease of 1.5% compared to $679.8 million in the second quarter of 2022. Loss from operations was $24.0 million, primarily due to 2023 net divestiture losses of $54.2 million, compared to income from operations of $38.1 million in the second quarter of 2022. Net loss was $49.5 million, or $0.54 diluted loss per share, compared to Net income of $10.5 million, or $0.11 diluted earnings per share in the second quarter of 2022. Adjusted income from operations1 was $76.0 million, compared to $82.0 million in the second quarter of 2022. Adjusted diluted earnings per share1 was $0.43, compared to $0.48 in the second quarter of last year. Cash flow from operations for the six months ended June 30, 2023 was an inflow of $154.9 million, compared to an outflow of $18.4 million in the same period of 2022. Free cash flow2 was an inflow of $91.2 million for the six months ended June 30, 2023, compared to an outflow of $88.4 million, primarily due to FCPA payments of $75.8 million in 2022.

KEY BUSINESS HIGHLIGHTS:        

  • Grew organic revenues1 2.3% compared to the second quarter of 2022 with Regulated Waste and Compliance Services (“RWCS”) growing 4.7%.
  • Reduced our Credit Agreement defined debt leverage ratio to 2.70X.
  • Improved free cash flow2 in the first half of 2023 by $179.6 million compared to 2022.
  • Divested our businesses in Brazil, Republic of Korea, Australia, and Singapore for net proceeds of approximately $84 million.

“In the second quarter, we achieved our key business priority of lowering our debt leverage ratio below 3.0X and to the lowest level since 2015. We also made significant progress in executing our portfolio optimization by exiting businesses in four countries and we remain on track to deploy the ERP to U.S. RWCS in the third quarter,” said Cindy J. Miller, President and Chief Executive Officer. “Our first half financial performance came in line with our full-year 2023 guidance, which we are reaffirming.”

SECOND
QUARTER FINANCIAL RESULTS


U.S. Generally Accepted Accounting Principles (GAAP) Results

  • Revenues in the second quarter were $669.5 million, compared to $679.8 million in the second quarter of 2022. The decrease was primarily due to impacts of divestitures of $24.0 million and unfavorable foreign exchange rates of $1.2 million, partially offset by organic revenue growth of $14.9 million. Organic revenues in RWCS grew $19.7 million, while Secure Information Destruction (“SID”) organic revenues were lower by $4.8 million.
  • Loss from operations in the second quarter was $24.0 million compared to Income from operations of $38.1 million in the second quarter of 2022. The $62.1 million decrease was primarily due to 2023 net divestiture losses of $54.2 million, higher incentive and stock-based compensation of $9.7 million, and higher fleet costs of $4.9 million, partially offset by lower bad debt expense of $8.9 million.
  • Net loss in the second quarter was $49.5 million, or $0.54 diluted loss per share, compared to Net income of $10.5 million, or $0.11 diluted earnings per share in the second quarter of 2022. The $60.0 million decrease was primarily attributable to lower Income from operations of $62.1 million, as explained above.
  • Cash flow from operations for the six months ended June 30, 2023 was an inflow of $154.9 million, compared to an outflow of $18.4 million in the same period of 2022. The year-over-year increase of $173.3 million was primarily driven by lower FCPA settlement payments of $67.6 million; accounts receivable improvements of $52.1 million, primarily due to an improvement in Days Sales Outstanding; higher cash generated from operating income of $23.3 million; lower annual incentive compensation payments of $22.3 million; and other working capital improvements of $8.0 million.
  • Cash paid for capital expenditures for the six months ended June 30, 2023 was $63.7 million, compared to $70.0 million in the same period of 2022.


Non-GAAP Results



1,2

  • For the second quarter of 2023, organic revenues1 increased 2.3%, which excludes the impacts of divestitures and foreign exchange rates. RWCS organic revenues1 increased 4.7% while SID decreased 2.1%.
  • Adjusted income from operations1 was $76.0 million, compared to $82.0 million in the second quarter of 2022. As a percentage of revenues, the 70 basis points decrease was mainly due to higher incentive and stock-based compensation of 150 basis points and higher fleet costs of 70 basis points, partially offset by lower bad debt expense of 130 basis points.
  • Adjusted diluted earnings per share1 was $0.43, compared to $0.48 in the second quarter of 2022. Excluding the impacts of divestitures and foreign exchange rates of $0.01, the remaining $0.04 decrease was driven by higher incentive and stock-based compensation of $0.08 and higher fleet costs of $0.04. These were partially offset by lower bad debt expense of $0.07 and lower tax expense of $0.01.
  • Free cash flow2 for the six months ended June 30, 2023 was an inflow of $91.2 million, compared to an outflow of $88.4 million in the same period of 2022. The $179.6 million increase was primarily due to higher cash flow from operations of $173.3 million, as explained above, and lower cash paid for capital expenditures of $6.3 million.

CONFERENCE CALL INFORMATION

Stericycle is holding its second quarter earnings conference call on Thursday, July 27, 2023, at 8:00 a.m. central time. Dial (833) 470-1428 in the U.S., (833) 950-0062 in Canada, or visit investors.stericycle.com for global dial-in numbers. Upon dialing the number, you will be prompted to enter the Access Code: 119356. To access presentation materials or listen to the call via an internet webcast, visit investors.stericycle.com.

The second quarter earnings call is being recorded and a replay will be available approximately one hour after the end of the conference call until August 24, 2023. To access a replay of the call, dial (866) 813-9403 and enter the Replay Access Code: 979851. A replay of the webcast will also be available at investors.stericycle.com.

NON-GAAP FINANCIAL MEASURES

Non-GAAP financial measures are reconciled to the most comparable U.S. GAAP measures in the schedules attached hereto.

ABOUT STERICYCLE

Stericycle, Inc., is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people and brands, promotes health and well-being and safeguards the environment. Stericycle serves customers in the U.S. and 12 countries with solutions for regulated waste and compliance services and secure information destruction. For more information about Stericycle, please visit stericycle.com.


1. Adjusted financial measures are Non-GAAP measures and exclude adjusting items as described and reconciled to comparable U.S. GAAP financial measures in the Reconciliation of U.S. GAAP to Non-GAAP Financial Measures contained in this Press Release.


2. Free cash flow is calculated as Net cash from operating activities less Capital expenditures.

SAFE HARBOR STATEMENT

This document may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. When we use words such as “believes”, “expects”, “anticipates”, “estimates”, “may”, “plan”, “will”, “goal”, or similar expressions, we are making forward-looking statements. Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of our management about future events and are therefore subject to risks and uncertainties, which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Factors that could cause such differences include, among others, inflationary cost pressure in labor, supply chain, energy, and other expenses, decreases in the volume of regulated wastes or personal and confidential information collected from customers, the ability to implement the remaining phases of our ERP system, and disruptions resulting from deployment of our ERP system, disruptions in our supply chain, disruptions in or attacks on information technology systems, labor shortages, a recession or economic disruption in the U.S. and other countries, SOP pricing volatility or pricing volatility in other commodities, rising interest rates or a downgrade in our credit rating resulting in an increase in interest expense, changing market conditions in the healthcare industry, competition and demand for services in the regulated waste and secure information destruction industries, foreign exchange rate volatility in the jurisdictions in which we operate, changes in governmental regulation of the collection, transportation, treatment and disposal of regulated waste or the proper handling and protection of personal and confidential information, the level of government enforcement of regulations governing regulated waste collection and treatment or the proper handling and protection of personal and confidential information, charges related to portfolio optimization or the failure of acquisitions or divestitures to achieve the desired results, failure to consummate transactions with respect to non-core businesses, the obligations to service substantial indebtedness and comply with the covenants and restrictions contained in our credit agreements and notes, political, economic, and other risks related to our foreign operations, pandemics and the resulting impact on the results of operations, long-term remote work arrangements which may adversely affect our business, supply chain disruptions, disruptions in transportation services, restrictions on the ability of our team members to travel, closures of our facilities or the facilities of our customers and suppliers, changes in the volume of paper processed by our secure information destruction business and the revenue generated from the sale of SOP, weather and environmental changes related to climate change, requirements of customers and investors for net carbon zero emissions strategies, and the introduction of regulations for greenhouse gases, which could negatively affect our costs to operate, the outcome of pending, future or settled litigation or investigations including the investigation by the DEA discussed in our SEC reports and litigation or investigations with respect to the U.S. Foreign Corrupt Practices Act and foreign anti-corruption laws, failure to maintain an effective system of internal control over financial reporting, as well as other factors described in our filings with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We disclaim any obligation to update or revise any forward-looking or other statements contained herein other than in accordance with legal and regulatory obligations.

 
STERICYCLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF
(LOSS) INCOME

(Unaudited)


 
In millions, except per share data


  Three Months Ended June 30,


    Six Months Ended June 30,


    2023   % Revenues       2022   % Revenues     %
Change
      2023     %
Revenues

    2022   %
Revenues

  %
Change

Revenues $ 669.5     100.0   %   $ 679.8     100.0   %   (1.5 ) %   $ 1,353.8     100.0   %   $ 1,344.0     100.0   %   0.7   %
Cost of revenues   418.4     62.5   %     419.3     61.7   %   (0.2 ) %     841.7     62.2   %     839.0     62.4   %   0.3   %
Gross profit   251.1     37.5   %     260.5     38.3   %   (3.6 ) %     512.1     37.8   %     505.0     37.6   %   1.4   %
Selling, general and administrative expenses   220.9     33.0   %     222.4     32.7   %   (0.7 ) %     436.9     32.3   %     461.0     34.3   %   (5.2 ) %
Divestiture losses, net   54.2     8.1   %           %   nm     59.2     4.4   %           %   nm
(Loss) income from operations   (24.0 )   (3.6 ) %     38.1     5.6   %   (163.0 ) %     16.0     1.2   %     44.0     3.3   %   (63.6 ) %
Interest expense, net   (19.1 )   (2.9 ) %     (18.5 )   (2.7 ) %   3.2   %     (39.5 )   (2.9 ) %     (34.8 )   (2.6 ) %   13.5   %
Other expense, net   (0.6 )   (0.1 ) %     (0.7 )   (0.1 ) %   (14.3 ) %     (0.4 )     %     (1.5 )   (0.1 ) %   (73.3 ) %
(Loss) income before income taxes   (43.7 )   (6.5 ) %     18.9     2.8   %   (331.2 ) %     (23.9 )   (1.8 ) %     7.7     0.6   %   (410.4 ) %
Income tax expense   (5.8 )   (0.9 ) %     (8.4 )   (1.2 ) %   (31.0 ) %     (14.3 )   (1.1 ) %     (11.3 )   (0.8 ) %   26.5   %
Net (loss) income   (49.5 )   (7.4 ) %     10.5     1.5   %   nm     (38.2 )   (2.8 ) %     (3.6 )   (0.3 ) %   nm
Net (loss) income attributable to noncontrolling interests         %           %   nm     (0.1 )     %     (0.2 )     %   (50.0 ) %
Net (loss) income attributable to Stericycle, Inc. common shareholders $ (49.5 )   (7.4 ) %   $ 10.5     1.5   %   nm   $ (38.3 )   (2.8 ) %   $ (3.8 )   (0.3 ) %   nm
(Loss) income per common share attributable to Stericycle, Inc. common shareholders:                                                  
Basic $ (0.54 )         $ 0.11           nm   $ (0.41 )         $ (0.04 )         nm
Diluted $ (0.54 )         $ 0.11           nm   $ (0.41 )         $ (0.04 )         nm
Weighted average number of common shares outstanding:                                                  
Basic   92.5             92.1                   92.3             92.0              
Diluted   92.5             92.2                   92.3             92.0              
nm – percentage change not meaningful for comparison


 

STATISTICS – U.S. GAAP AND NON-GAAP ADJUSTED FINANCIAL MEASURES

(Unaudited)
 
In millions, except per share data                              
  Three Months Ended June 30,   Six Months Ended June 30,
    2023     %
Revenues
    2022     %
Revenues
    2023     %
Revenues
    2022     %
Revenues

Statistics – U.S. GAAP
                             
Effective tax rate (13.3) %         44.4 %       (59.8) %         146.8 %    

Statistics – Adjusted 



(1)

                             
Adjusted gross profit $ 254.5     38.0 %   $ 260.5     38.3 %   $ 515.5     38.1 %   $ 505.0     37.6 %
Adjusted selling, general and administrative expenses $ 178.5     26.7 %   $ 178.5     26.3 %   $ 354.8     26.2 %   $ 364.0     27.1 %
Adjusted income from operations $ 76.0     11.4 %   $ 82.0     12.1 %   $ 160.7     11.9 %   $ 141.0     10.5 %
Adjusted EBITDA $ 102.0     15.2 %   $ 109.0     16.0 %   $ 213.3     15.8 %   $ 195.3     14.5 %
Adjusted net income attributable to common shareholders $ 40.3     6.0 %   $ 44.1     6.5 %   $ 85.5     6.3 %   $ 73.1     5.4 %
Adjusted effective tax rate   28.5 %         29.8 %         29.1 %         30.0 %    
Adjusted diluted earnings per share $ 0.43         $ 0.48         $ 0.93         $ 0.79      
Adjusted diluted shares outstanding   92.7           92.2           92.7           92.2      

(1)  

Adjusted financial measures are Non-GAAP measures and exclude adjusting items as described and reconciled to comparable U.S. GAAP financial measures in the Reconciliation of U.S. GAAP to Non-GAAP Financial Measures contained in this Press Release.
  
 

STERICYCLE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)
 
In millions, except per share data      
  June 30, 2023   December 31, 2022
ASSETS      
Current Assets:      
Cash and cash equivalents $ 30.7     $ 56.0  
Accounts receivable, less allowance for doubtful accounts of $44.1 in 2023 and $53.3 in 2022   410.3       414.5  
Prepaid expenses   33.5       33.2  
Other current assets   52.7       55.0  
Total Current Assets   527.2       558.7  
Property, plant and equipment, less accumulated depreciation of $662.0 in 2023 and $657.7 in 2022   692.5       715.7  
Operating lease right-of-use assets   431.1       398.9  
Goodwill   2,751.9       2,784.9  
Intangible assets, less accumulated amortization of $873.2 in 2023 and $823.3 in 2022   743.8       811.1  
Other assets   66.6       64.8  
Total Assets $ 5,213.1     $ 5,334.1  
LIABILITIES AND EQUITY      
Current Liabilities:      
Current portion of long-term debt $ 15.6     $ 22.3  
Bank overdrafts         2.9  
Accounts payable   207.0       213.5  
Accrued liabilities   243.2       244.1  
Operating lease liabilities   99.6       91.2  
Other current liabilities   53.7       47.9  
Total Current Liabilities   619.1       621.9  
Long-term debt, net   1,293.7       1,484.0  
Long-term operating lease liabilities   352.4       329.0  
Deferred income taxes   429.0       427.0  
Long-term income taxes payable   9.3       11.8  
Other liabilities   26.8       35.9  
Total Liabilities   2,730.3       2,909.6  
       
Commitments and contingencies      
       
EQUITY      
Common stock (par value $0.01 per share, 120.0 shares authorized, 92.5 and 92.2 issued and outstanding in 2023 and 2022, respectively)   0.9       0.9  
Additional paid-in capital   1,299.8       1,285.4  
Retained earnings   1,372.5       1,410.8  
Accumulated other comprehensive loss   (191.0 )     (276.9 )
Total Stericycle, Inc.’s Equity   2,482.2       2,420.2  
Noncontrolling interests   0.6       4.3  
Total Equity   2,482.8       2,424.5  
Total Liabilities and Equity $ 5,213.1     $ 5,334.1  
 

STERICYCLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)
 
In millions      
  Six Months Ended June 30,
    2023       2022  
OPERATING ACTIVITIES:      
Net loss $ (38.2 )   $ (3.6 )
Adjustments to reconcile net loss to net cash from operating activities:      
Depreciation   52.6       54.3  
Intangible amortization   56.3       63.2  
Stock-based compensation expense   17.8       12.6  
Deferred income taxes   4.9       5.2  
Divestiture losses, net   59.2        
Asset impairments, (gain) loss on disposal of property plant and equipment and other charges   3.1       0.3  
Other, net   1.2       1.6  
Changes in operating assets and liabilities:      
Accounts receivable   (1.3 )     (53.4 )
Prepaid expenses   (1.6 )     10.0  
Accounts payable   (1.5 )     (12.5 )
Accrued liabilities   8.4       (91.6 )
Other assets and liabilities   (6.0 )     (4.5 )
Net cash from operating activities   154.9       (18.4 )
INVESTING ACTIVITIES:      
Capital expenditures   (63.7 )     (70.0 )
Proceeds from divestiture of businesses, net   88.9       1.6  
Other, net   1.2       0.8  
Net cash from investing activities   26.4       (67.6 )
FINANCING ACTIVITIES:      
Repayments of long-term debt and other obligations   (10.0 )     (8.4 )
Proceeds from foreign bank debt   0.1        
Repayments of foreign bank debt   (0.3 )     (0.1 )
Repayments of term loan   (50.0 )      
Proceeds from credit facility   601.0       732.5  
Repayments of credit facility   (737.7 )     (637.9 )
Repayment of bank overdrafts   (2.9 )     (0.6 )
Payments of finance lease obligations   (1.4 )     (1.3 )
Proceeds from issuance of common stock, net of (payments of) taxes from withheld shares   (5.2 )     (5.2 )
Payments to noncontrolling interest   (1.5 )      
Net cash from financing activities   (207.9 )     79.0  
Effect of exchange rate changes on cash and cash equivalents   1.3       (2.7 )
Net change in cash and cash equivalents   (25.3 )     (9.7 )
Cash and cash equivalents at beginning of period   56.0       55.6  
Cash and cash equivalents at end of period $ 30.7     $ 45.9  
       
SUPPLEMENTAL CASH FLOW INFORMATION:      
Interest paid, net of capitalized interest $ 38.0     $ 31.9  
Income taxes paid, net $ 13.7     $ 4.0  
Capital expenditures in Accounts payable $ 21.9     $ 30.8  
Free Cash Flow (1) $ 91.2     $ (88.4 )

(1)   

Free Cash Flow is calculated as Net cash from operating activities less Capital expenditures
 

Table 1–A: REVENUE CHANGES BY SERVICE AND SEGMENT (UNAUDITED) –

THREE
MONTHS ENDED
JUNE 30, 2023
and
2022

 
  Three Months Ended June 30,
  In millions       Components of Change (%)

(1)
    2023     2022   Change ($)   Change
(%)
  Organic
Growth


(2)
  Divestitures   Foreign
Exchange


(3)
Revenue by Service                          
Regulated Waste and Compliance Services $ 444.7   $ 448.4   $ (3.7 )   (0.8) %   4.7 %   (5.1) %   (0.1) %
Secure Information Destruction Services   224.8     231.4     (6.6 )   (2.9) %   (2.1) %   (0.4) %   (0.4) %
Total Revenues $ 669.5   $ 679.8   $ (10.3 )   (1.5) %   2.3 %   (3.5) %   (0.2) %
North America                          
Regulated Waste and Compliance Services $ 366.4   $ 365.6   $ 0.8     0.2 %   4.8 %   (4.2) %   (0.2) %
Secure Information Destruction Services   198.8     203.0     (4.2 )   (2.1) %   (1.6) %   %   (0.4) %
Total North America Segment $ 565.2   $ 568.6   $ (3.4 )   (0.6) %   2.4 %   (2.7) %   (0.3) %
International                          
Regulated Waste and Compliance Services $ 78.3   $ 82.8   $ (4.5 )   (5.4) %   3.9 %   (9.4) %   0.5 %
Secure Information Destruction Services   26.0     28.4     (2.4 )   (8.5) %   (5.4) %   (3.3) %   0.1 %
Total International Segment $ 104.3   $ 111.2   $ (6.9 )   (6.2) %   1.4 %   (7.9) %   0.4 %
See footnote descriptions below Table 1 – C 
 

Table 1–B: REVENUE CHANGES BY SERVICE AND SEGMENT (UNAUDITED) –

SIX
MONTHS ENDED
JUNE 30, 2023
and
2022
 
   
  Six Months Ended June 30,  
  In millions       Components of Change (%)

(1)
 
    2023     2022   Change ($)   Change
(%)
  Organic
Growth


(2)
  Divestitures   Foreign
Exchange


(3)
 
Revenue by Service                            
Regulated Waste and Compliance Services $ 896.0   $ 901.2   $ (5.2 )   (0.6) %   4.6 %   (4.4) %   (0.8) %
Secure Information Destruction Services   457.8     442.8     15.0     3.4 %   4.6 %   (0.2) %   (1.0) %
Total Revenues $ 1,353.8   $ 1,344.0   $ 9.8     0.7 %   4.6 %   (3.0) %   (0.8) %
North America                            
Regulated Waste and Compliance Services $ 735.1   $ 727.8   $ 7.3     1.0 %   5.4 %   (4.1) %   (0.2) %
Secure Information Destruction Services   403.5     384.5     19.0     4.9 %   5.5 %   %   (0.6) %
Total North America Segment $ 1,138.6   $ 1,112.3   $ 26.3     2.4 %   5.4 %   (2.7) %   (0.3) %
International                            
Regulated Waste and Compliance Services $ 160.9   $ 173.4   $ (12.5 )   (7.2) %   1.3 %   (5.5) %   (3.0) %
Secure Information Destruction Services   54.3     58.3     (4.0 )   (6.9) %   (1.4) %   (1.6) %   (3.9) %
Total International Segment $ 215.2   $ 231.7   $ (16.5 )   (7.1) %   0.6 %   (4.5) %   (3.2) %
See footnote descriptions below Table 1 – C  
   



Table 1–C: COMPONENTS OF REVENUE CHANGE IN DOLLARS (UNAUDITED)
 
(In millions)
  Three Months Ended

June 30, 2023
  Six Months Ended

June 30, 2023
Organic Growth (2) $ 14.9     $ 61.7  
Divestitures   (24.0 )     (40.6 )
Foreign exchange (3)   (1.2 )     (11.3 )
Total Change $ (10.3 )   $ 9.8  

(1)   

Components of Change (%) in summation may not crossfoot to the total Change (%) due to rounding.

(2)   

Organic growth is the change in revenues which includes SOP (sorted office paper) pricing and volume and excludes the impact of divestitures and foreign exchange.

(3)   

The comparisons at constant currency rates (foreign exchange) reflect comparative local currency balances at prior period’s foreign exchange rates. Stericycle calculated these percentages by taking current period reported Revenues less the respective prior period reported Revenues, divided by the prior period reported Revenues, all at the respective prior period’s foreign exchange rates. This measure provides information on the change in Revenues assuming that foreign currency exchange rates have not changed between the prior and the current period. Management believes the use of this measure aids in the understanding of changes in Revenues without the impact of foreign currency.
 

 
RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

Table 2-A:
THREE
MONTHS ENDED
JUNE 30, 2023
and
2022

(In millions, except per share data)
  Three Months Ended June 30, 2023
  Gross Profit   Selling,

General and Administrative

Expenses
  (Loss) Income
from Operations
  Net (Loss) Income


Attributable to
Common Shareholders


c
  Diluted (Loss)
Earnings Per
Share
U.S. GAAP Financial Measures $ 251.1   $ 220.9     $ (24.0 )   $ (49.5 )   $ (0.54 )
Adjustments:                  
ERP and System Modernization 1       (5.4 )     5.4       4.1       0.04  
Intangible Amortization 2       (28.1 )     28.1       21.8       0.24  
Portfolio Optimization 3             54.2       53.8       0.58  
Litigation, Settlements and Regulatory Compliance 4       (8.9 )     8.9       6.7       0.07  
Asset Impairments 5   3.4           3.4       3.4       0.04  
Total Adjustments   3.4     (42.4 )     100.0       89.8       0.97  
Adjusted Financial Measures

a

 
$ 254.5   $ 178.5     $ 76.0     $ 40.3     $ 0.43  
Depreciation           26.0          
Adjusted EBITDA

b
        $ 102.0          
 

(In millions, except per share data)
  Three Months Ended June 30, 2022
  Gross Profit   Selling,

General and Administrative

Expenses
  Income from
Operations
  Net Income

Attributable to
Common


Shareholders
 

c
  Diluted Earnings
Per Share
U.S. GAAP Financial Measures $ 260.5   $ 222.4     $ 38.1   $ 10.5   $ 0.11
Adjustments:                  
ERP and System Modernization 1       (3.5 )     3.5     2.6     0.03
Intangible Amortization 2       (30.8 )     30.8     23.9     0.26
Portfolio Optimization 3                    
Litigation, Settlements and Regulatory Compliance 4       (9.6 )     9.6     7.1     0.08
Asset Impairments 5                    
Total Adjustments       (43.9 )     43.9     33.6     0.37
Adjusted Financial Measures

a
$ 260.5   $ 178.5     $ 82.0   $ 44.1   $ 0.48
Depreciation           27.0        
Adjusted EBITDA 

b
        $ 109.0        
 

(In millions, except per share data)
  Second
Quarter
2023
Change Compared to
Second
Quarter
2022
  Gross Profit   Selling,

General and
Administrative
Expenses
  (Loss) Income
from Operations
  Net (Loss) Income

Attributable to
Common
Shareholders 
  Diluted (Loss)
Earnings Per
Share
U.S. GAAP Financial Measures $ (9.4 )   $ (1.5 )   $ (62.1 )   $ (60.0 )   $ (0.65 )
Adjustments:                  
ERP and System Modernization         (1.9 )     1.9       1.5       0.01  
Intangible Amortization         2.7       (2.7 )     (2.1 )     (0.02 )
Portfolio Optimization               54.2       53.8       0.58  
Litigation, Settlements and Regulatory Compliance         0.7       (0.7 )     (0.4 )     (0.01 )
Asset Impairments   3.4             3.4       3.4       0.04  
Total Adjustments   3.4       1.5       56.1       56.2       0.60  
Adjusted Financial Measures $ (6.0 )   $     $ (6.0 )   $ (3.8 )   $ (0.05 )
Depreciation           (1.0 )        
Adjusted EBITDA         $ (7.0 )        
 

The following table provides adjustments to Income from operations categorized as follows:

(In millions)
  Three Months Ended June 30,
  2023   2022
Non-Cash Related 6 $ 83.8   $ 30.8
Cash Related   16.2     13.1
Total $ 100.0   $ 43.9
 

Non-cash related adjustments include the following:

(In millions)
  Three Months Ended June 30, 2023
  Depreciation and
Impairments of Property,
Plant and Equipment
  Amortization of
Intangibles
  Divestiture
Losses (Gains),
net
  Total
Adjustments:              
Intangible Amortization2 $   $ 28.1   $   $ 28.1
Portfolio Optimization3           52.3     52.3
Asset Impairments5   3.4             3.4
Total Non-Cash Charges $ 3.4   $ 28.1   $ 52.3   $ 83.8
 

(In millions)
  Three Months Ended June 30, 2022
  Depreciation and
Impairments of Property,
Plant and Equipment
  Amortization of
Intangibles
  Divestiture
Losses (Gains),
net
  Total
Adjustments:              
Intangible Amortization2 $         —           $         30.8           $         —           $         30.8        
Total Non-Cash Charges $                    $         30.8           $                    $         30.8        
U.S. GAAP results for the three months ended June 30, 2023 and 2022 include:
 

  1. ERP and System Modernization: In 2023 and 2022, Selling, General, and Administrative expenses (“SG&A”) includes consulting and professional fees related to our ERP and system modernization.
  2. Intangible Amortization: Intangible amortization expense from acquisitions.
  3. Portfolio Optimization: In 2023, Divestitures losses, net includes aggregate net losses of $54.2 million (inclusive of $1.9 million related to deal costs) related to International divestitures of Brazil, Republic of Korea, Australia, Singapore, and other businesses.
  4. Litigation, Settlements, and Regulatory Compliance: In 2023 and 2022, SG&A includes $5.2 million (which includes FCPA monitor related fees of $2.4 million) and $3.5 million, respectively, of primarily consulting and professional fees and estimated contingent liability provisions related to certain litigation, settlement and regulatory compliance matters. Additionally in 2023, SG&A includes a settlement charge associated with a vendor dispute of $4.0 million, other settlement charges of $0.6 million, and a FCPA settlement release of $0.9 million. Additionally in 2022, SG&A includes a $3.5 million settlement charge related to a multi-year indirect tax related Internal Revenue Service (“IRS”) examination and FCPA settlement expense of $0.4 million.
  5. Asset Impairments: In 2023, Cost of Revenues (“COR”) includes an impairment of $3.4 million in International associated with certain long-lived assets, primarily property, plant and equipment, in Romania.
  6. Non-Cash Related Adjustments: In 2023 and 2022, non-cash related adjustments include $83.8 million and $30.8 million, respectively, consisting of intangible amortization, portfolio optimization, and asset impairment items.
  1. The Non-GAAP financial measures contained in this press release are reconciled to the most comparable measures calculated in accordance with U.S. GAAP in the schedules attached to this release. Management believes the Non-GAAP financial measures are useful measures of Stericycle’s performance because they provide additional information about Stericycle’s operations and exclude certain adjusting items, allowing better evaluation of underlying business performance and better period-to-period comparability. The Non-GAAP financial measures contained in this press release may not be calculated in the same manner as certain other Non-GAAP financial measures and are used solely to evaluate management’s performance for incentive compensation purposes. All Non-GAAP financial measures are intended to supplement the applicable U.S. GAAP measures and should not be considered in isolation from, or a replacement for, financial measures prepared in accordance with U.S. GAAP and may not be comparable to or calculated in the same manner as Non-GAAP financial measures published by other companies.
  2. Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (Adjusted EBITDA) is (Loss) income from operations excluding certain adjusting items, depreciation and intangible amortization.
  3. Under the Net (Loss) Income Attributable to Common Shareholders column, adjustments are shown net of tax in aggregate of $10.2 million and $10.3 million for the three months ended June 30, 2023 and 2022, respectively, based on applying the statutory tax rate for the jurisdictions in which the adjustment occurred or, by adjusting the tax effect to consider the impact of applying an annual effective tax rate on an interim basis. For purposes of reconciling adjusted diluted earnings per share with respect to taxes period-over-period, the company utilizes a “rate approach” to highlight the impact of the adjusted tax rate. It is computed by multiplying the prior period adjusted rate by the current period adjusted income before taxes to determine the expected tax expense. Such expected tax expense is then compared to actual tax expense. Expected tax in excess of actual tax variance is favorable; actual tax in excess of expected tax variance is unfavorable. The variance divided by diluted shares outstanding at the end of the period yields the impact on earnings per share. Management believes the use of this measure best aids in explaining the impact of a changing tax rate.
 

Table 2-B:
SIX
MONTHS ENDED
JUNE 30, 2023
and
2022
 
(In millions, except per share data)
  Six Months Ended June 30, 2023
  Gross Profit   Selling, 

General and
Administrative
Expenses
  Income from
Operations
  Net (Loss) Income 

Attributable to
Common
Shareholders

 

c
  Diluted (Loss)
Earnings Per
Share
U.S. GAAP Financial Measures $ 512.1   $ 436.9     $ 16.0   $ (38.3 )   $ (0.41 )
Adjustments:                  
ERP and System Modernization 1       (8.1 )     8.1     6.1       0.07  
Intangible Amortization 2       (56.3 )     56.3     43.7       0.47  
Portfolio Optimization 3       (0.6 )     59.8     59.1       0.64  
Litigation, Settlements and Regulatory Compliance 4       (17.1 )     17.1     11.5       0.12  
Asset Impairments 5   3.4           3.4     3.4       0.04  
Total Adjustments   3.4     (82.1 )     144.7     123.8       1.34  
Adjusted Financial Measures 

a
$ 515.5   $ 354.8     $ 160.7   $ 85.5     $ 0.93  
Depreciation           52.6        
Adjusted EBITDA 

b
        $ 213.3        
 

(In millions, except per share data)
  Six Months Ended June 30, 2022
  Gross Profit   Selling, 

General and
Administrative
Expenses
  Income from
Operations
  Net (Loss) Income 

Attributable to
Common
Shareholders 


c
  Diluted (Loss)
Earnings Per
Share
U.S. GAAP Financial Measures $ 505.0   $ 461.0     $ 44.0   $ (3.8 )   $ (0.04 )
Adjustments:                  
ERP and System Modernization 1       (9.1 )     9.1     6.8       0.07  
Intangible Amortization 2       (63.2 )     63.2     49.1       0.53  
Portfolio Optimization 3       (1.3 )     1.3     1.0       0.01  
Litigation, Settlements and Regulatory Compliance 4       (23.4 )     23.4     20.0       0.22  
Asset Impairments 5                        
Total Adjustments       (97.0 )     97.0     76.9       0.83  
Adjusted Financial Measures 

a
$ 505.0   $ 364.0     $ 141.0   $ 73.1     $ 0.79  
Depreciation           54.3        
Adjusted EBITDA
 

b
        $ 195.3        
 

(In millions, except per share data)
  Year-to-Date
2023
Change Compared to
2022
  Gross Profit   Selling, 

General and
Administrative
Expenses
  Income from
Operations
  Net (Loss) Income 

Attributable to
Common
Shareholders 
  Diluted (Loss)
Earnings Per
Share
U.S. GAAP Financial Measures $ 7.1   $ (24.1 )   $ (28.0 )   $ (34.5 )   $ (0.37 )
Adjustments:                  
ERP and System Modernization       1.0       (1.0 )     (0.7 )      
Intangible Amortization       6.9       (6.9 )     (5.4 )     (0.06 )
Portfolio Optimization       0.7       58.5       58.1       0.63  
Litigation, Settlements and Regulatory Compliance       6.3       (6.3 )     (8.5 )     (0.10 )
Asset Impairments   3.4           3.4       3.4       0.04  
Total Adjustments   3.4     14.9       47.7       46.9       0.51  
Adjusted Financial Measures $ 10.5   $ (9.2 )   $ 19.7     $ 12.4     $ 0.14  
Depreciation           (1.7 )        
Adjusted EBITDA         $ 18.0          
 

The following table provides adjustments to Income from operations categorized as follows:

(In millions)
  Six Months Ended June 30,
    2023     2022
Non-Cash Related6 $ 116.9   $ 63.2
Cash Related   27.8     33.8
Total $ 144.7   $ 97.0
 

Non-cash related adjustments include the following:

(In millions)
  Six Months Ended June 30, 2023
  Depreciation and
Impairments of Property,
Plant and Equipment
  Amortization of
Intangibles
  Divestiture
Losses (Gains),
net
  Total
Adjustments:              
Intangible Amortization 2 $   $ 56.3       $ 56.3
Portfolio Optimization3           57.2     57.2
Asset Impairments 5   3.4             3.4
Total Non-Cash Charges $ 3.4   $ 56.3   $ 57.2   $ 116.9
 

(In millions)
  Six Months Ended June 30, 2022
  Depreciation and
Impairments of Property,
Plant and Equipment
  Amortization of
Intangibles
  Divestiture
Losses (Gains),
net
  Total
Adjustments:              
Intangible Amortization 2 $   $ 63.2       $ 63.2
Total Non-Cash Charges $   $ 63.2   $   $ 63.2
U.S. GAAP results for the six months ended June 30, 2023 and 2022 include:
  1. ERP and System Modernization: In 2023 and 2022, SG&A includes consulting and professional fees related to our ERP and system modernization.
  2. Intangible Amortization: Intangible amortization expense from acquisitions.
  3. Portfolio Optimization: In 2023 Divestitures losses, net includes aggregate net losses of $59.2 million (inclusive of $2.0 million related to deal costs) related to International divestitures of Brazil, Republic of Korea, Australia, Singapore, a container manufacturing operation, and other businesses. In 2023 and 2022, SG&A includes consulting and professional fees associated with our Portfolio Optimization efforts of $0.6 million and $1.3 million, respectively.
  4. Litigation, Settlements, and Regulatory Compliance: In 2023 and 2022, SG&A includes $12.4 million (which includes FCPA monitor related fees of $5.8 million) and $10.3 million, respectively, of primarily consulting and professional fees and estimated contingent liability provisions net of releases related to certain litigation, settlement and regulatory compliance matters. Additionally in 2023, SG&A includes a value-added tax reclaim credit of $6.0 million, a settlement charge associated with a vendor dispute of $6.0 million, other settlement charges of $5.6 million, and a FCPA settlement release of $0.9 million. Additionally in 2022, SG&A includes FCPA settlement expense of $9.6 million and a settlement charge related to a multi-year indirect tax related IRS examination of $3.5 million.
  5. Asset Impairments: In 2023, COR includes an impairment of $3.4 million in International associated with certain long-lived assets, primarily property, plant and equipment, in Romania.
  6. Non-Cash Related Adjustments: In 2023 and 2022, non-cash related adjustments include $116.9 million and $63.2 million, respectively, consisting of intangible amortization, portfolio optimization, and asset impairment items.
  1. The Non-GAAP financial measures contained in this press release are reconciled to the most comparable measures calculated in accordance with U.S. GAAP in the schedules attached to this release. Management believes the Non-GAAP financial measures are useful measures of Stericycle’s performance because they provide additional information about Stericycle’s operations and exclude certain adjusting items, allowing better evaluation of underlying business performance and better period-to-period comparability. The Non-GAAP financial measures contained in this press release may not be calculated in the same manner as certain other Non-GAAP financial measures and are used solely to evaluate management’s performance for incentive compensation purposes. All Non-GAAP financial measures are intended to supplement the applicable U.S. GAAP measures and should not be considered in isolation from, or a replacement for, financial measures prepared in accordance with U.S. GAAP and may not be comparable to or calculated in the same manner as Non-GAAP financial measures published by other companies.
  2. Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (Adjusted EBITDA) is Income from operations excluding certain adjusting items, depreciation and intangible amortization.
  3. Under the Net Loss Attributable to Common Shareholders column, adjustments are shown net of tax in aggregate of $20.9 million and $20.1 million for the six months ended June 30, 2023 and 2022, respectively, based on applying the statutory tax rate for the jurisdictions in which the adjustment occurred or, by adjusting the tax effect to consider the impact of applying an annual effective tax rate on an interim basis. For purposes of reconciling adjusted diluted earnings per share with respect to taxes period-over-period, the company utilizes a “rate approach” to highlight the impact of the adjusted tax rate. It is computed by multiplying the prior period adjusted rate by the current period adjusted income before taxes to determine the expected tax expense. Such expected tax expense is then compared to actual tax expense. Expected tax in excess of actual tax variance is favorable; actual tax in excess of expected tax variance is unfavorable. The variance divided by diluted shares outstanding at the end of the period yields the impact on earnings per share. Management believes the use of this measure best aids in explaining the impact of a changing tax rate.

FOR FURTHER INFORMATION CONTACT:

Stericycle Investor Relations 847-607-2012
Stericycle Media Relations 847-964-2288